Real-World Treatment Patterns, Healthcare Resource Utilization, Costs, and Survival Among Medicare Beneficiaries with Diffuse Large B-Cell Lymphoma (DLBCL)

被引：1
|
作者：
Garg, Mahek [1 ]
Huntington, Scott F. [2 ]
Puckett, Justin [3 ]
Kamal-Bahl, Sachin [4 ]
Raut, Monika [1 ]
Ryland, Katherine Elizabeth [5 ]
Doshi, Jalpa [6 ]
机构：
[1] Merck & Co Inc, Ctr Observat & Real World Evidence, Rahway, NJ USA
[2] Yale Univ, Dept Internal Med, Sect Hematol, Sch Med, New Haven, CT USA
[3] COVIA Hlth Solut, Philadelphia, PA USA
[4] COVIA Hlth Solut, Lansdale, PA USA
[5] Merck & Co Inc, Kenilworth, NJ USA
[6] Univ Penn, Perelman Sch Med, Div Gen Internal Med, Philadelphia, PA USA
来源：
BLOOD | 2022年 / 140卷
关键词：
D O I：
10.1182/blood-2022-158026
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
下载
收藏
页码：10814 / 10815
页数：2
相关论文
共 50 条
  • [21] Costs of relapsed diffuse large B-cell lymphoma among Medicare patients
    Huntington, Scott
    Keshishian, Allison
    McGuire, Michael
    Xie, Lin
    Baser, Onur
    LEUKEMIA & LYMPHOMA, 2018, 59 (12) : 2880 - 2887
  • [22] Healthcare Resource Utilization and Associated Costs of German Patients with Diffuse Large B-Cell Lymphoma (DLBCL) - a Retrospective Health Claims Data Analysis
    Borchmann, Peter
    Papadimitrious, Michael S.
    Mahlich, Joerg
    Riou, Sybille
    Werner, Barbara
    BLOOD, 2022, 140 : 7932 - 7932
  • [23] Burden of illness and outcomes in second-line large B-cell lymphoma treatment: real-world analysis of Medicare beneficiaries
    Kilgore, Karl M.
    Mohammadi, Iman
    Wong, Anny C.
    Snider, Julia T.
    Cheng, Paul
    Schroeder, Amy
    Patel, Anik R.
    FUTURE ONCOLOGY, 2021, 17 (35) : 4837 - 4847
  • [24] Tafasitamab for the Treatment of Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) in the US Real-World Setting
    Saverno, Kimberly
    Savill, Kristin M. Zimmerman
    Feinberg, Bruce
    Galvin, John
    Pathak, Prathamesh
    Gordon, Sarah
    Amoloja, Theresa
    Llorente, Mae
    Epperla, Narendranath
    Nastoupil, Loretta J.
    BLOOD, 2023, 142
  • [25] Trends in the improvement in survival among patients with diffuse large B-cell lymphoma (DLBCL)
    MacDougall, Kira
    Day, Silas
    Nipp, Ryan David
    Hall, Spencer
    Zhao, Yan D.
    Al-Juhaishi, Taha
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (28) : 147 - 147
  • [26] THE BURDEN OF HEALTHCARE COST AMONG RELAPSED DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) PATIENTS: (A SEER MEDICARE DATASET EXAMINATION)
    Flowers, C.
    Chastek, B.
    Becker, L.
    Mahmoud, D.
    Dulac, E.
    HAEMATOLOGICA, 2014, 99 : 784 - 785
  • [27] HEALTHCARE RESOURCE USE (HCRU) AND ASSOCIATED COSTS AMONG PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) TREATED WITH CAR-T CELLS IN FRANCE - A REAL-WORLD STUDY USING DATA FROM PMSI
    Di Blasi, R.
    Thieblemont, C.
    Haioun, C.
    Sala, Sackmann L.
    Mayaud, A. C.
    Diez-Andreu, P.
    Bugnard, F.
    Goguillot, M.
    Finzi, J.
    Chillotti, L.
    Benard, S.
    VALUE IN HEALTH, 2022, 25 (12) : S79 - S80
  • [28] Real-World Treatment Patterns, Overall Survival, Healthcare Resource Utilization, and Costs Among US Elderly Patients with Mantle Cell Lymphoma (MCL) after Failure of Covalent Btki Treatment
    Squires, Patrick
    Puckett, Justin T.
    Ryland, Katherine Elizabeth
    Kamal-Bahl, Sachin
    Raut, Monika
    Doshi, Jalpa A.
    Huntington, Scott F.
    BLOOD, 2023, 142
  • [29] TREATMENT PATTERNS AMONG PATIENTS WITH RELAPSED/REFRACTORY (RIR) DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) WHO ARE INELIGIBLE FOR TRANSPLANTATION - A REAL-WORLD STUDY USING FRENCH PMSI
    Di Blasi, R.
    Thieblemont, C.
    Haioun, C.
    Mayaud, A. C.
    Sala, Sackmann L.
    Diez-Andreu, P.
    Bugnard, F.
    Goguillot, M.
    Chillotti, L.
    Finzi, J.
    Benard, S.
    VALUE IN HEALTH, 2022, 25 (12) : S218 - S218
  • [30] Survival Patients Newly Diagnosed with Diffuse Large B-Cell Lymphoma (DLBCL) - Real World Evidence from Germany
    Borchmann, Peter
    Papadimitrious, Michael
    Riou, Sybille
    Mahlich, Joerg
    Werner, Barbara
    BLOOD, 2022, 140 : 7919 - 7919
12345